Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

OncoMed Pharmaceuticals Inc

+ Add to Watchlist

OMED:US

23.5500 USD 0.6200 2.70%

As of 17:20:00 ET on 05/27/2015.

Snapshot for OncoMed Pharmaceuticals Inc (OMED)

Open: 23.0500 Day's Range: 22.6000 - 23.5900 Volume: 69,703
Previous Close: 22.9300 52wk Range: 16.5700 - 29.8300 1-Yr Rtn: +1.51%

Stock Chart for OMED

No chart data available.
  • OMED:US 23.5500
  • 1D
  • 1M
  • 1Y
22.9300
Interactive OMED Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for OMED

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -1.7000
Est. EPS (USD) (12/2015) -0.9320
Est. PEG Ratio -
Market Cap (M USD) 706.93
Shares Outstanding (M) 30.02
30 Day Average Volume 146,703
Price/Book (mrq) 10.8115
Price/Sale (ttm) 16.2284
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/07/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for OMED

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for OMED

OncoMed Pharmaceuticals, Inc. provides biotechnology research and development. The Company synthesizes oncogenic mutations in stem cells that allows the cells to grow without normal limitations in attempts to exploit therapies that selectively target tumor initiating cells. OncoMed Pharmaceuticals serves the healthcare industry and cancer therapy patients in the United States.

Paul J HastingsPresident/CEOJohn A LewickiExec VP/Chief Scientific Ofcr
Sunil PatelSenior VP:Finance/CFOAustin GurneySenior VP:Molecular & Cellular
More Company Profile & Key Executives for OMED

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil